IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Richard A. Couch et al.

Serial No.: 10/774,697

Group Art Unit: 1614

Filed: February 10, 2004

Examiner: Unknown

For: ENANTIOMERIC AMPHETAMINE COMPOSITIONS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

under § 1.53(d); within three months of application; OR before the mailing of a finance.	
application; OR	ne filing date of a national application other than a CPA
RCE). Under 37 C.F.R. § 1.97(c), this is	the actual filing date of the national phase of a PCT
	rst substantive office action (including after filing of an
	nformation disclosure statement is filed after the periods, but before the mailing date of:
a final rejection under 3 termination of prosecution a notice of allowance un	· · · · · · · · · · · · · · · · · · ·

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing dowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a	notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited 1	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
		_	s of materials listed but not attached were cited in an international search dated
		Not re	quired by 37 CFR § 1.98.
	\boxtimes	Copies	s of the materials listed are attached (except for the foregoing).

Non-	English	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art
		O = non-written disclosure P = intercalated document
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application L = cited for another reason
		& = publication of member of same patent family
		Translation of other relevant information on foreign search report
		[insert necessary translation here]
Other	Informa	<u>ation</u>
Paym	ent of Fo	ees Due (If Any):
	A chec	ck for \$ covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Csaba Henter, Reg. No. 50,908 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: PHAMRA-0148

Date: April 1, 2005

CH:pdr

		1	P	T	O	/:	S	B/	96	Α	١,	(0	8	-()(1)	1	
-	-	 _	_	_		_	_				_						_	

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute fo	r form 1449A/PT	0	W. B. IBA	DEMARK	Complete if Known	
				Application Number	10/774,697	
INFOR	MATION	DISC	CLOSURE	Filing Date	February 10, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Richard A. COUCH et al.	
				Group Art Unit	1615	
(u	se as many sh	eets as n	ecessary)	Examiner Name	Unknown	
Sheet	1	of	2	Attorney Docket Number	PHARMA-0148	_

	U.S. PATENT DOCUMENTS										
Examiner Initials *	Cite No.1	U.S. Patent Docume	nt Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY						
	1	6,605,300	B1	Beth A. Burnside et al.	08-12-2003						
		""									

	FOREIGN PATENT DOCUMENTS													
			Foreign Patent Doc	ument		Date of Publication of	Pages, Columns, Lines, Where Relevant							
Examiner Initials*	Cite No.1	Office ³	Number⁴	Kind Code⁵ (<i>if</i> known)	Name of Patentee or Applicant of Cited Document		Passages or Relevant Figures Appear	۳⁵						
,														

Examiner Date			
Signature Considered	Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box + APR 0 1 2005 Approved for use through 10/31/2002. OMB 0651-0031 Approved for use through 10/31/2002. OMB 0651-0031 Under the Paperwork Reduction Act of 1995, no persons are requirectly respond to a collection of information unless it contains a valid OMB control number	Substitute for form 14494/PTO	THEFT	Complete if Known	1
		R 0 1 2005	Approved for use through 10/31/2002. OMB 0651- ent and Trademark Office: U.S. DEPARTMENT OF COMME	-0031 ERCE
		TPE		

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

DEBOO		_
•	Complete if Known	
Application Number	10/774,697	
Filing Date	February 10, 2004	
First Named Inventor	Richard A. COUCH et al.	
Group Art Unit	1615	
Examiner Name	Unknown	
Attorney Docket Number	PHARMA-0148	

xaminer Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2	Psychopharmacology 50, 171-175 (1976), Sleep: Effects of <i>d</i> - and <i>l</i> -Amphetamine in Man and in Rat, Ernest Hartmann et al.	*
	3	The Journal of Pharmacology and Experimental Therapeutics, Vol. 194, No. 1, Amphetamine: Evaluation of <i>d</i> - And <i>I</i> -Isomers As Releasing Agents And Uptake Inhibitors For ³ H-Dopamine and ³ H-Norepinephrine In Slices Of Rat Neostraitum And Cerebral Cortex, Richard E. Heikkila et al., pages 47-56.	
	4	Biochemical Pharmacology, Vol. 25, pp. 447-451, Effects Of The <i>d</i> - And <i>l</i> -Isomers Of Amphetamine On Uptake, Release And Catabolism Of Norepinephrine, Dopamine And 5-Hydroxytryptamine In Several Regions Of Rat Brain, John C. Holmes et al.	
		·	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.